Details

Autor(en) / Beteiligte

• Schulman, Sam
• Kearon, Clive
• Kakkar, Ajay K
• Mismetti, Patrick
• Schellong, Sebastian
• Eriksson, Henry
• Baanstra, David
• Schnee, Janet
• Goldhaber, Samuel Z

Titel

Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism

Ist Teil von

• The New England journal of medicine, 2009-12, Vol.361 (24), p.2342-2352

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2009

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• In this comparative-effectiveness trial, the oral direct thrombin inhibitor dabigatran was shown to be as effective as warfarin in the prevention of recurrent venous thromboembolism. Bleeding complications were similar. Dabigatran therapy offers the advantage that monitoring of anticoagulation is not necessary. In this comparative-effectiveness trial, the oral direct thrombin inhibitor dabigatran was shown to be as effective as warfarin in the prevention of recurrent venous thromboembolism. Dabigatran therapy offers the advantage that monitoring of anticoagulation is not necessary. Venous thromboembolism affects 1 to 2 adults per 1000 annually and is the third most common cause of vascular death after myocardial infarction and stroke. 1 , 2 The current standard treatment is rapidly acting parenteral anticoagulation for 5 to 7 days followed by at least 3 months of treatment with a vitamin K antagonist. 3 Treatment with a vitamin K antagonist requires frequent monitoring of the international normalized ratio (INR), and multiple interactions of vitamin K antagonists with foods and other drugs have been reported. 4 Dabigatran etexilate (hereafter termed dabigatran) is an orally available, potent, direct inhibitor of thrombin. It is rapidly . . .